Volv Global SA hat dies direkt geteilt
Versatile leader in clinical development operations, building the bridges for wellbeing, between biotech, health tech, clinical researchers, clinicians and patients
It’s been a pleasure to talk with Jessica Lynn from Patient Worthy about the challenges in rare disease diagnosing and how new technologies can help in this. With Volv Global SA #inTrigue #inClude #driveforchange #rarediseaseresearch #iainhealthare
🦾 How can we use #AI to address challenges in rare disease? I’ve seen a lot of chatter online recently about AI and machine learning. Some people are (understandably) skeptical; others see its broad application as undeniably beneficial. In the rare disease space, I view AI as having huge potential. There are over 300 million people living with #RareDiseases worldwide. And there are over 10,000 known rare diseases, with new genetic conditions being discovered all the time. Since these diseases are often not well-understood or have small communities — I recently interviewed Gabby, who is the only known person with her rare disease in the US — rare diseases are hard to diagnosis. People often wait years, sometimes decades, for answers. AI can read patterns in data and identify where undiagnosed patients exist. What groups of symptoms or characteristics physicians should look out for. I recently spoke with Leon van Wouwe, the Chief Innovation Director at Volv Global SA. Volv Global is a world-class leader in applying AI to healthcare with a focus on rare or difficult-to-diagnose diseases. In our interview, we cover the growing onset of artificial intelligence in healthcare, the importance of remembering the human dimension, and how Volv’s inTrigue methodology has already been used to improve diagnostics in Fabry disease and Pompe disease in the UK. Read now 🔗: https://lnkd.in/etpJJMSz #RareDisease #ArtificialIntelligence #PompeDisease #FabryDisease #HealthTech